Valbiotis SA (EPA: ALVAL)

Market Cap	21.28M
Revenue (ttm)	527.00K
Net Income (ttm)	-8.94M
Shares Out	15.76M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,902
Open	1.350
Previous Close	1.364
Day's Range	1.330 - 1.410
52-Week Range	1.070 - 5.300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Valbiotis

Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 52
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVAL

Financial Performance

In 2023, Valbiotis's revenue was 4.73 million, an increase of 502.93% compared to the previous year's 785,000. Losses were -7.37 million, -40.16% less than in 2022.